 This meta-analysis that we're talking about assumes that everyone was on metformin monotherapy as background, which is what we found in the trials. 80 to 90% were on metformin. So we're not talking about comparisons to metformin. Kalyani says it's important to take into account someone's entire health picture to choose the diabetes medicines that are best for them.